Drug Profile
Fluticasone propionate - Ellodi Pharmaceuticals
Alternative Names: APT 1011; EUR 1100Latest Information Update: 19 Jan 2023
Price :
$50
*
At a glance
- Originator Aptalis
- Developer Adare Pharmaceuticals; Ellodi Pharmaceuticals
- Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Inorganic sulfur compounds; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Eosinophilic oesophagitis
Most Recent Events
- 29 Dec 2022 Ellodi Pharmaceuticals initiates a phase III FLUTE-3 trial for Eosinophilic oesophagitis (In adults, In the elderly) in USA (PO) (NCT05634746)
- 02 Dec 2022 Ellodi Pharmaceuticals plans a phase III FLUTE-3 trial for Eosinophilic oesophagitis (In adults) in December 2022 (NCT05634746)
- 24 Oct 2022 Ellodi Pharmaceuticals completes a phase-III FLUTE-2 trial in Eosinophilic oesophagitis (In adults, In the elderly) in Australia, Spain and USA (PO) (NCT04281108) (EudraCT2019-001521-27)